Satyanarayana Chava – CEO, Laurus Labs, India
Dr. Satyanarayana Chava, founder and CEO of Laurus Labs, provides insights into the distinctive model that has allowed Laurus to become one of the world’s leading API companies as well…
Laurus Labs Limited, together with its subsidiaries, engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (APIs) in India and internationally. It operates through Laurus Generics APIs, Laurus Generics Finished Dosage Forms (FDF), Laurus Synthesis, and Laurus Ingredients divisions.
The Laurus Generics APIs division develops, manufactures, and sells APIs and advanced intermediates for anti-retroviral (ARV), Hepatitis C, cardiovascular, antidiabetic, anti-asthmatic, gastroenterology, oncology, and ophthalmic therapeutic areas. The Laurus Generics Finished Dosage Forms division develops and manufactures oral solid formulations, such as ARVs, anti-diabetic, cardiovascular, and proton pump inhibitors.
The Laurus Synthesis division provides contract development and manufacturing services for pharmaceutical companies. The Laurus Ingredients division manufactures and sells speciality ingredients for use in the nutraceutical/dietary supplements and cosmeceutical products. In addition, it offers chemistry, IP development, business support, and related services to the pharmaceutical community. The company was incorporated in 2005 and is based in Hyderabad, India. Laurus Labs Limited is a subsidiary of Aptuit LLC.
Dr. Satyanarayana Chava, founder and CEO of Laurus Labs, provides insights into the distinctive model that has allowed Laurus to become one of the world’s leading API companies as well…
Sir Dr. Huz, CEO and trustee of the Wockhardt Foundation and executive director of Wockhardt, discusses the role the Foundation plays in low- and middle-income areas across India, and how integrating simple…
The secretary-general of the Indian Drug Manufacturers Association (IDMA) gives his insight into the current state of the Indian pharma industry, the IDMA’s role in raising the quality of Indian-made…
The Indian joint secretary for commerce and industry, interviewed at CPhI Worldwide 2014 in Paris, discusses India’s place in the global pharmaceutical landscape, and emphasizes the country’s contribution to the…
You have only recently been appointed Managing Director for the first time in your career. How did your first year with UCB India go so far? My first year at…
Novo Nordisk seems somewhat of an exception to the MNCs that recently entered India, as it already set up its HQ in Bangalore in 1994. How do you explain this…
The Indian biotechnology sector is quite particular. In spite of its young age, the industry has grown significantly in a very short time. In your view, where does the Indian…
Novo Nordisk seems somewhat of an exception to the MNCs that recently entered India, as it already set up its HQ in Bangalore in 1994. How do you explain this…
PAREXEL has had a long-term commitment to India. Could you give us a brief overview of your activities in the country? PAREXEL offers clinical development services throughout India. In 2004,…
TCS Life Sciences and Healthcare vertical was created within the Tata Group 10 years ago. Can you explain to the readers, how such a diversified group such as Tata decided…
Arch Pharmalabs started its operations in 1999 when you bought a plant in Hyderabad with a turnover of 2Mn USD. 12 years later, you have grown to a 300Mn USD…
Cachet Pharmaceuticals was founded in 1978, what have been your main achievements? We started as a manufacturing company. In the early 1990s we started our own marketing and since then…
With almost EUR 9bn turnover and more than 22,000 people worldwide, Royal DSM has truly grown into an MNC. Within the global market, there is no doubt that India has…
See our Cookie Privacy Policy Here
